Read by QxMD icon Read


Cassandra De Gasperis-Brigante, Sukhbir S Singh, George Vilos, Sari Kives, Ally Murji
OBJECTIVE: To determine pregnancy and fetal outcomes following treatment with ulipristal acetate (UPA) for symptomatic uterine fibroids. METHODS: We conducted a systematic review and case series. We searched MEDLINE, EMBASE, PubMed, Web of Science, and Cochrane Register from inception to February 2017. From January 2014 to July 2017, we carried out a multi-centre retrospective chart review. All human studies that reported at least one pregnancy following UPA treatment were included...
August 2018: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
Angela Santoro, Giuseppe Angelico, Damiano Arciuolo, Frediano Inzani, Francesco Fanfani, Daniela Romualdi, Giovanni Scambia, Gian Franco Zannoni
INTRODUCTION: To study the clinical, pathological and therapeutic implications of ulipristal acetate (UPA) treatment failure in patients affected by uterine smooth muscle tumors. CASE PRESENTATION: Two patients affected by uterine leiomyosarcoma were preoperatively diagnosed as uterine leiomyomas and, thus, treated conservatively with UPA and morcellation. Both patients experienced a worsening of symptoms (persistent bleeding) after 3 month of treatment with UPA...
August 2018: Medicine (Baltimore)
Na Gan, Qiaomei Sun, Man Zhang, Peixiao Tang, Ludan Zhao, Tonghui Xie, Yongkui Zhang, Hui Li
Interaction between ulipristal acetate (UPA) and human serum albumin (HSA) was investigated in simulated physiological environment using multi-spectroscopic and computational methods. Fluorescence experiments showed that the quenching mechanism was static quenching, which was confirmed by the time-resolved fluorescence. Binding constants (Ka ) were found to be 1 × 105 L mol-1 , and fluorescence data showed one binding site. Thermodynamic constants suggested the binding process was mainly controlled by electrostatic interactions...
July 30, 2018: Journal of Biomolecular Structure & Dynamics
So-Jin Shin, Jinyoung Kim, Seungmee Lee, Jongwoo Baek, Jin Eui Lee, Chiheum Cho, Eunyoung Ha
Uterine leiomyoma is a benign tumor that grows within the muscle tissue of the uterus. Ulipristal acetate (UPA) is a pre‑operative drug used to reduce the size of leiomyoma. The aim of the present study was to examine the in vitro mechanistic details of action of UPA on uterine leiomyomas. Primary cultures of leiomyoma cells were isolated from patient myomectomy specimens and incubated in the presence or absence of UPA at various concentrations. The proliferation, cell viability and doubling time properties of the treated cells were analyzed...
October 2018: International Journal of Molecular Medicine
Jorge E Shortrede, Maria M Montt-Guevara, Gisela Pennacchio, Michele Finiguerra, Andrea Giannini, Alessandro D Genazzani, Tommaso Simoncini
Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM) used for emergency contraception and for the medical management of symptomatic uterine fibroids (UF). Treatment with UPA turns in amenorrhea and UF volume reduction. Treatment with UPA is associated with the frequent development of benign, transitory endometrial changes known as SPRM-associated endometrial changes (PAECs). Why PAECs develop and their biological or cellular basis is unknown. Sex steroids, including estrogen and progesterone, are established modulators of the actin cytoskeleton in various cells, including endometrial cells...
2018: Frontiers in Endocrinology
Benjamin J G Illingworth, Martin Hirsch, James M N Duffy
No abstract text is available yet for this article.
July 2018: Obstetrics and Gynecology
Benjamin Tuschy, Mirja Gabbert, Christel Weiss, Amadeus Hornemann, Anne Wuhrer, Marc Sütterlin, Sebastian Berlit
OBJECTIVE: To evaluate changes in sexuality in women treated with Ulipristal acetate (UPA) due to symptomatic uterine fibroids. STUDY DESIGN: A total of 102 women with symptomatic uterine fibroids undergoing conservative therapy with UPA were enrolled in this observational study. Sexuality was evaluated before and after a three month UPA treatment using the Female Sexual Functioning Index (FSFI) as well as the Sexual Activity Questionnaire (SAQ). Before treatment was initiated, participants additionally filled in a standardised questionnaire addressing the expected changes in sexuality due to UPA...
June 16, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
W Elger, B Schneider, Z Killeen, K Jewgenow, M Dehnhard, M Friedrich, B Santhamma, R Wedemeyer, K Nickisch
A guinea pig model for new HEC methods is proposed. Two targets for HEC (Hormonal Emergency Contraception), ovulation and conception (post-mating study), were investigated using adjusted PRM treatments: (a) Ovulation inhibition study: Injections on cycle days 10-17, study of ovarian histology on day 18; (b) post-mating study: Injections on cycle days 1 and 2; rate of pregnant females was recorded at autopsy on day 18. P plasma levels permitted assessment of effects on ovulation in non-conceiving animals. RESULTS: (a) All controls had recently ovulated...
June 11, 2018: Journal of Steroid Biochemistry and Molecular Biology
S Oscoz-Jaime, M Larrea-García, M J Mitxelena-Eceiza, N Abián-Franco
No abstract text is available yet for this article.
May 31, 2018: Actas Dermo-sifiliográficas
Piotr Czuczwar, Anna Stepniak, Pawel Milart, Tomasz Paszkowski, Slawomir Wozniak
BACKGROUND: To assess and compare the influence of three fibroid treatment options: supracervical hysterectomy, ulipristal acetate and uterine artery embolization on ovarian reserve. METHODS: Prospective, observational, open-label study performed at the 3rd Chair and Department of Gynecology of the Medical University of Lublin, Poland. Premenopausal Caucasian women with symptomatic uterine fibroids were recruited into 3 groupspatients qualified for supracervical hysterectomies; patients qualified for preoperative ulipristal acetate (UPA) treatment scheduled for supracervical hysterectomies or myomectomies; patients qualified for uterine artery embolization (UAE)...
June 1, 2018: Journal of Ovarian Research
Guillaume E Courtoy, Jacques Donnez, Jérôme Ambroise, Pablo Arriagada, Mathieu Luyckx, Etienne Marbaix, Marie-Madeleine Dolmans
RESEARCH QUESTION: Does ulipristal acetate (UPA) modify the expression of genes related to apoptosis or the extracellular matrix in uterine myomas and are any modifications associated with a clinical response? DESIGN: Targeted analysis of 176 apoptosis- or extracellular-matrix-related genes was conducted using polymerase chain reaction (PCR) arrays. Relevant results were validated by quantitative PCR. Four groups were established: responsive short-term (one course, n = 9), responsive long-term (two to four courses, n = 9), non-responsive (n = 9), and the control group who was not given any hormone therapy (n = 9)...
August 2018: Reproductive Biomedicine Online
Jack Charles Collins, Carl Richard Schneider, Rebekah Jane Moles
OBJECTIVE: To explore the supply of emergency contraception (EC) from Australian community pharmacies after the introduction of ulipristal acetate (UPA) and to explore pharmacists' knowledge, decision-making, attitudes and beliefs surrounding supplying EC. STUDY DESIGN: A mixed-methods approach of mystery shopping with structured interview was employed. From August to November 2017, 20 pharmacy students mystery-shopped 10 community pharmacies in metropolitan Sydney, Australia, requesting "the morning after pill...
May 9, 2018: Contraception
Gian Benedetto Melis, Manuela Neri, Bruno Piras, Anna Maria Paoletti, Silvia Ajossa, Monica Pilloni, Maria Francesca Marotto, Valentina Corda, Alessandra Saba, Elena Giancane, Valerio Mais
The medical strategy to antagonize myoma size and related-symptoms is to reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH agonist (GnRHa) or with compounds that antagonize progesterone stimulatory activity on myomas. Selective progesterone receptor modulators (SPRMs) bind progesterone receptor (PR), leading to both agonist and antagonist effects. The result of SPRMs's action is tissue-specific and it depends on the particular affinity and strength of each SPRM. Area covered: Ulipristal acetate (UPA) is the first SPRM registered for myoma treatment...
May 2018: Expert Opinion on Investigational Drugs
Saúl Lira-Albarrán, Marta Durand, David Barrera, Claudia Vega, Rocio García Becerra, Lorenza Díaz, Janice García-Quiroz, Claudia Rangel, Fernando Larrea
In order to get further information on the effects of ulipristal acetate (UPA) upon the process of decidualization of endometrium, a functional analysis of the differentially expressed genes in endometrium (DEG) from UPA treated-versus control-cycles of normal ovulatory women was performed. A list of 1183 endometrial DEG, from a previously published study by our group, was submitted to gene ontology, gene enrichment and ingenuity pathway analyses (IPA). This functional analysis showed that decidualization was a biological process overrepresented...
April 27, 2018: Molecular and Cellular Endocrinology
Jacques Donnez, Guillaume E Courtoy, Olivier Donnez, Marie-Madeleine Dolmans
Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), offers new therapeutic options for the clinical management of large uterine fibroids associated with heavy menstrual bleeding or with other moderate or severe symptoms (bulk symptoms, pelvic pain, decreased quality of life). SPRM are synthetic compounds that exert an agonist or antagonist effect on target tissues by their binding to progesterone receptors. UPA reduces fibroid size, controls bleeding in a high percentage of women and significantly improves quality of life...
April 21, 2018: Reproductive Biomedicine Online
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
Meritxell Gracia, Marta Alcalà, Janisse Ferreri, Mariona Rius, Cristina Ros, María Adela Saco, María Ángeles Martínez-Zamora, Francisco Carmona
STUDY OBJECTIVE: To study the effects of ulipristal acetate (UPA) on adenomyosis-associated clinical symptoms. DESIGN: A retrospective, single-center observational study (Canadian Task Force classification II-2). SETTING: A university tertiary referral center. PATIENTS: Premenopausal women (163) with adenomyosis and symptomatic uterine myomas (41 patients, A + F group) versus a control group with only myomas (122 patients, F group) treated with the first course of UPA...
April 4, 2018: Journal of Minimally Invasive Gynecology
Bo Seong Yun, Seok Ju Seong, Yong Wook Jung, Mi-La Kim, Hyo Sook Bae, Mi Kyoung Kim, Sung Shin Shim
OBJECTIVES: Ulipristal acetate (UPA) is a selective progesterone receptor modulator, which has been used to treat uterine fibroids. Many published reports about the outcomes indicate effective control of bleeding and reduction in the fibroid volume following both short- and long-term therapy. However, the reported volume reduction varies across different reports. Therefore, the purpose of this study was to investigate the factors that can affect the volume reduction of uterine fibroids, after short-term UPA therapy in patients with symptomatic uterine fibroids...
May 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
Pavel Šauer, Alžběta Stará, Oksana Golovko, Olga Valentová, Adam Bořík, Roman Grabic, Hana Kocour Kroupová
Vast numbers of xenobiotics are known still to be present in treated municipal wastewater treatment plant (WWTP) effluents. Some of these possess endocrine-disrupting potency and pose risks for exposed aquatic animals. We searched for 17 potential environmental contaminants having affinity to the progesterone receptor. Relative potency values of these progesterone receptor-active chemicals were obtained. On the basis of relative potencies and measured environmental concentrations, the contribution of progestins to measured progestagenic activities was evaluated...
June 15, 2018: Water Research
Natalie Woodhead, Rachel Pounds, Shirin Irani, Poonam Pradhan
Ulipristal acetate (UPA), is a selective progesterone-receptor modulator, it decreases fibroid size and reduces menstrual bleeding. We reviewed its use at the Heart of England Foundation Trust (HEFT), one of the largest prescribing trusts in the UK. The electronic records of patients treated with UPA from January 2013 to August 2015 were reviewed. One hundred and thirty four patients received UPA, 20 women (15%) received a second course. Eighty percent reported subjective global improvements in symptoms after the first course; 45...
March 12, 2018: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"